BTIG analyst Mark Massaro lowered the firm’s price target on Personalis (PSNL) to $6 from $8 and keeps a Buy rating on the shares. The company reported an “uncharacteristic” miss related to pharma order timing, though did deliver good clinical testing growth for its molecular residual disease test, the analyst tells investors in a research note. The firm added that the company reaffirmed its goal to obtain two Medicare coverage determinations by year-end 2025, though it still lowered its estimates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSNL:
- Personalis price target lowered to $8.50 from $9 at H.C. Wainwright
- Personalis: Strong Molecular Testing Growth and Strategic MRD Focus Support Buy Rating
- Personalis Reports Q2 2025 Financial Results
- Personalis: Buy Rating Amidst Challenges and Opportunities in MRD Growth
- Personalis reports Q2 EPS (23c), consensus (24c)